Text Size

Mifepristone and Misoprostol for Fetal Demise (MIMID)

This study has been completed.
Sponsor:
Collaborator:
Anonymous
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177372
First received: September 12, 2005
Last updated: October 20, 2008
Last verified: October 2008
History of Changes
  Purpose

This is a pilot clinical trial to evaluate whether the medical management of early pregnancy failure with mifepristone and misoprostol is an effective and acceptable treatment. Subjects with early pregnancy failure receive mifepristone followed 24 hours later by vaginal misoprostol for medical management. Subjects then return on study day 3 for a repeat ultrasound to assess passage of pregnancy tissue. subjects who still have a gestational sac present at Day 3 receive a second dose of vaginal misoprostol. All subjects have a follow-up at Day 15, by phone for those who passed the pregnancy with the first dose of misoprostol, and in person for those who received a second dose. Questionnaires are administered at the beginning and end of the study to determine acceptability.


Condition Intervention Phase
Early Pregnancy Failure
Anembryonic Gestation
Fetal Demise
 Drug: mifepristone/misoprostol
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Mifepristone and Misoprostol for the Treatment of Early Pregnancy Failure: a Pilot Clinical Trial

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • to determine if medical management with mifepristone and misoprostol for early pregnancy failure is an effective and acceptable treatment [ Time Frame: 1-2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • to evaluate if the treatment of early pregnancy failure with mifepristone and misoprostol is as effective as induced abortion with these medications [ Time Frame: 1-2 weeks ] [ Designated as safety issue: No ]
  • to assess if mifepristone/misoprostol treatment is acceptable to patients with early pregnancy failure [ Time Frame: 1-2 weeks ] [ Designated as safety issue: No ]
  • to assess the predictors/indicators for successful mifpristone/misoprostol treatment in patients with early pregnancy failure [ Time Frame: 1-2 weeks ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: January 2005
Study Completion Date: September 2005
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
 Drug: mifepristone/misoprostol
mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
Other Name: Mifeprix/Cytotec

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: healthy hemodynamically stable females with a non-viable pregnancy

-

Exclusion Criteria:

  • orthostatic hypotension, contraindication to either mifepristone or misoprostol, treatment during current pregnancy to provide surgical or medical evacuation of the uterus, evidence of ovarian hyperstimulation syndrome, known or suspected pelvic infection,known or suspected clotting defect or receiving anticoagulants, cardiovascular disease, current breastfeeding, pregnancy with and IUD in situ, current participation in another clinical trial, prior participation in this trial, suspected or confirmed endometrial AV malformation, clinical indication requiring the karyotyping of products of conception
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00177372

Locations
United States, Pennsylvania
Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Anonymous
Investigators
Principal Investigator: Mitchell D Creinin, MD Magee-Womens Hospital
  More Information

Publications:

Responsible Party: MItchell Creinin, MD, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00177372     History of Changes
Other Study ID Numbers: Pittirb0409119
Study First Received: September 12, 2005
Last Updated: October 20, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Mifepristone
Misoprostol
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptives, Postcoital, Synthetic
 Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents
Abortifacient Agents, Steroidal
Abortifacient Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics
Abortifacient Agents, Nonsteroidal

ClinicalTrials.gov processed this record on May 22, 2013